Trial · NCT03205995
Adverse events78
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 78
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | BRADYCARDIA | Cardiac disorders | OMS721 (Narsoplimab) | 1 | 6 | 2 |
| other | HAEMOLYSIS | Blood and lymphatic system disorders | OMS721 (Narsoplimab) | 2 | 6 | 4 |
| other | IRON DEFICIENCY ANAEMIA | Blood and lymphatic system disorders | OMS721 (Narsoplimab) | 1 | 6 | 1 |
| other | CARDIAC FAILURE | Cardiac disorders | OMS721 (Narsoplimab) | 1 | 6 | 5 |
| other | HYPERTROPHIC CARDIOMYOPATHY | Congenital, familial and genetic disorders | OMS721 (Narsoplimab) | 1 | 6 | 1 |
| other | ADRENAL INSUFFICIENCY | Endocrine disorders | OMS721 (Narsoplimab) | 1 | 6 | 1 |
| other | HYPERTHYROIDISM | Endocrine disorders | OMS721 (Narsoplimab) | 1 | 6 | 1 |
| other | ASCITES | Gastrointestinal disorders | OMS721 (Narsoplimab) | 1 | 6 | 1 |
| other | DIARRHOEA | Gastrointestinal disorders | OMS721 (Narsoplimab) | 1 | 6 | 1 |
| other | ENTEROCOLITIS | Gastrointestinal disorders | OMS721 (Narsoplimab) | 1 | 6 | 1 |
| other | GASTROINTESTINAL HAEMORRHAGE | Gastrointestinal disorders | OMS721 (Narsoplimab) | 1 | 6 | 1 |
| other | NAUSEA | Gastrointestinal disorders | OMS721 (Narsoplimab) | 1 | 6 | 1 |
| other | OESOPHAGEAL ULCER | Gastrointestinal disorders | OMS721 (Narsoplimab) | 1 | 6 | 1 |
| other | INJECTION SITE EXTRAVASATION | General disorders | OMS721 (Narsoplimab) | 2 | 6 | 2 |
| other | INJECTION SITE HAEMATOMA | General disorders | OMS721 (Narsoplimab) | 1 | 6 | 1 |
| other | INJECTION SITE PAIN | General disorders | OMS721 (Narsoplimab) | 2 | 6 | 3 |
| other | OEDEMA PERIPHERAL | General disorders | OMS721 (Narsoplimab) | 1 | 6 | 2 |
| other | PYREXIA | General disorders | OMS721 (Narsoplimab) | 3 | 6 | 4 |
| other | CHRONIC ALLOGRAFT NEPHROPATHY | Immune system disorders | OMS721 (Narsoplimab) | 1 | 6 | 1 |
| other | HYPERSENSITIVITY | Immune system disorders | OMS721 (Narsoplimab) | 1 | 6 | 2 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03205995/events